Other

Unither Developpement

Direction Et Priorites Sa

Perovitch, Philippe

Maury, Marc

Philippe Perovitch

Marc Maury

Jean Deymes

Francis Gadrat

Bertrand Chastenet

Jean-Pierre Dumonteix

Tatiana Galperine

A galenical form for the administration transmucously of at least one active ingredient, characterized in that the active ingredient is in a stable and complete dissolved state in a hydroalcoholic solution that includes at least 20% by mass of alcohol so as to allow rapid absorption of the active ingredient through the mucous membranes of the buccal cavity and/or the oropharynx. Uses of the galenical form are also disclosed.

Galenical form for the administration of active ingredients by transmucous means

A device for packaging, conserving, and extemporaneously preparing a plurality of active principles, including a reservoir having a compartment for containing a volume of liquid, the reservoir including a neck defining a dispenser opening; a head that is movable relative to the reservoir between a first distal position for conservation and a second proximate position for preparation; a leaktight closure mechanism; and a rupture mechanism for rupturing the closure mechanism. The closure mechanism is formed by a blister that contains at least two active principles and has at least two compartments, each compartment containing an active principle. The blister is fastened on the neck of the reservoir so as to close it, such that after opening the blister by the rupture mechanism, the active principles enter into contact with the liquid and dissolve therein.

Device for packaging, storing, and extemporaneously preparing a plurality of active principles

A galenical form for the buccal transmucous administration of at least one active ingredient of the triptan family, includes at least:

Galenical form for the administration of triptans by buccal transmucous means

A formulation for oral transmucosal administration of at least one active principle with antispasmodic and/or analgesic effect, including the active principle in base form and/or in salt form, an aqueous alcohol solution titrating at least 35&#xb0; alcohol by weight, the active principle being present in a state of stable and complete dissolution in the aqueous alcohol solution. Also, a method of preparing this formulation and its use for treating spastic crises.

Formulation for oral transmucosal administration of analgesic and/or antispasmodic molecules

A method and a pharmaceutical composition in the form of a hydroalcoholic solution in which at least one hypoglycemia-inducing/insulinotropic active principle is dissolved in a stable and complete manner at a dosage that is reduced by 30% to 50% compared with the usual oral unit dosage, for its trans-buccal mucosal application in the spot treatment of postprandial hyperglycemia in type II diabetes in man or animals. Also, disclosed is a method of preparing said formulation and to its specific use in the spot treatment of postprandial hyperglycemia (PPHG) in the context of type II diabetes.

Method and pharmaceutical compositions for trans-buccal mucosa treatment of postprandial hyperglycaemia in type II diabetes

A method of treating hypoptyalism in a subject is provided. The method includes administering to the subject a pharmaceutical composition that includes pilocarpine and a bioadhesive polymer. The composition dissolves sublingually in the mouth of the subject and adheres to mucous tissues in the buccopharyngeal cavity. The pilocarpine then dissolves and binds to muscarine receptors present in cells of the subject's salivary glands, endobuccal submucous glands and submaxillary glands, is then absorbed by the cells thereby stimulating the glands to produce saliva.

Use of pilocarpine for hypoptyalism treatment

The invention relates to a formulation for delivering by oral transmucosal administration at least one lipid-lowering active principle, preferably from the statin family, said formulation including said active principle in the base or salt form, an aqueous alcohol solution titrating at least 30&#xb0; alcohol, and optionally a pH correcting agent and/or an antioxidant, said active principle being in a stable and completely dissolved state in the aqueous alcohol solution. The invention also relates to a method of preparing said formulation and to the use thereof, preferably in single-dose packaging, for treating and preventing hyperlipemia and/or cardiovascular conditions.

Formulation for oral transmucosal administration of lipid-lowering drugs

The invention provides a device () for conserving and extemporaneously preparing at least one active principle prior to administration, the device comprising: a body () that is constituted by at least one compartment for containing at least one volume of pharmaceutical solvent () that is less than 5 mL; a head () constituted by at least one compartment for containing at least one active principle (), in particular a very small dose, and, in its top portion, by at least one dose-taking chamber () provided with a filter (), the head () being capable of taking up a first position Pfor conservation, in which said head () is in its distal position relative to the body (), and a second position Pfor preparation, in which said head () is in its proximal position relative to the body (); at least one wall () separating the body () and the head (); and rupture means () for rupturing said wall () so that the active principle () enters into contact with the solvent () and dissolves therein. The invention also seeks to use the device for conserving and extemporaneously preparing at least one active principle with a view to administering it.

Device for conserving, extemporaneously preparing, and administering an active principle

A process for local permucosal diffusion of amino acid salts of low dosage lipophlic non-steroidal anti-inflammatory or anti-mycotic molecules for an aqueous medicine for the treatment of bucco-pharyngeal ailments is disclosed. Compositions and tablets implementing this diffusion process are also disclosed.

Method for the diffusion of molecules which are insoluble in an aqueous medium and composition using said method

A galenical form for the transmucous administration of at least one active ingredient, characterized in that the active ingredient is paracetamol in a stable and complete dissolved state in a hydroalcoholic solution that includes at least 10% by mass of alcohol so as to allow fast absorption of the active ingredient through the mucous membranes of the buccal cavity and/or the oropharynx. A process for production and the uses of the galenical form are also disclosed.

Galenical form for the administration of paracetamol by transmucous means

The invention provides a packaging and administering device for administering a hydro-alcoholic solution by passing through a mucous membrane, the device comprising a deformable container for receiving at least one first fraction of the solution, a base that is secured to the container, and an administering tube that is secured to the base and that is suitable for receiving at least one second fraction of the solution, and that includes a cap. The tube includes a chamber for containing the at least one second solution and that is defined by two membranes, and the cap is movable in translation between two extreme positions and includes a needle for coming to pierce the two membranes in one of the extreme positions.

Device for packaging and delivering active principles in a hydroalcoholic solution

The invention provides a container for preparing and/or administering a very small volume of active principles in liquid form, the container comprising a head () suitable for taking up a conservation, first position Pin which said head () is in a distal position relative to the container, and an administration, second position Pin which said head () is in a proximal position relative to the container, said head () including a cannula () with at least one flow channel (), its length being adapted so that the free end of the flow channel () can enable delivery by sublingual and/or paragingival permeation, while the container is being held in the hand.

Device for packaging and sublingual administration of active principles

A salivary substitute is produced from egg white so as to have chemical, rheological and physiological properties that are analogous to those of natural human saliva. A packaging containing the salivary substitute and uses of the salivary substitute are also disclosed.

Salivary substitute

A process for treating the hemorrhage fluids of a patient at the time of a surgical procedure with the aim of carrying out an autotransfusion, includes a stage for recovering the hemorrhage fluids with simultaneous introduction of agents such as anticoagulant and/or diluting agents, at least one stage for the mechanical separation/concentration of this hemodiluted hemorrhage fluid in order to concentrate its content in red blood cells and partially purify it, this phase being collected in a sterile manner so as to be fit for injecting back to the patient. Also described is the related device.

Growing community of inventors

Le Temple, France

Philippe Perovitch